Australian universities produce world-class research and, increasingly, the companies that commercialise it. But a university spinout starts life with a negotiation most founders never face: the technology was invented inside an institution, the institution (usually) owns it, and the company must extract rights to it from a technology transfer office (TTO) before it can raise a dollar. The deal you strike with the TTO — what IP you get, on what terms, and what the university takes in return — is baked into every subsequent financing. Venture investors will read the licence before they read your deck, and a bad one is the most common reason deep tech deals die in due diligence.
First Question: Does the University Actually Own It?
Everyone at the table tends to assume the university owns the research. It’s worth checking, because the answer is less automatic than TTOs imply.
For staff inventors, ownership usually rests on the university’s IP policy and the employment contract. The famous wrinkle is University of Western Australia v Gray [2009] FCAFC 116, where the Full Federal Court held that UWA did not own patents developed by a professor of surgery: as French J put it at first instance (upheld on appeal), a duty to research is not a duty to invent, and no term could be implied giving the university his inventions — particularly given academic freedom to publish. Universities responded by tightening express IP provisions, so most modern academic contracts and policies do vest inventions in the institution — but the paperwork for long-running projects with staff who predate the current policy deserves real scrutiny, not assumption.
Students are the bigger trap. PhD and other higher-degree research students are not employees, and at most Australian universities the default position — stated in the university’s own IP policy — is that students own the IP they create, unless they’ve signed it away to join a funded project. Many core spinout technologies have a student’s fingerprints on them. If that student never signed an assignment, the university can’t licence what it doesn’t own, and your “exclusive” licence has a hole in it. The fix is the same one we’ve described for startup IP generally: trace every contributor, and get signed assignments or consents before the company takes its licence — not during a Series A scramble.
Then map the background IP — pre-existing university IP the spinout technology sits on — against the project IP the founders will create inside the company. The licence should define both precisely. A vague grant of “the Technology” invites a dispute later about whether an improvement made by your team belongs to you or flows back to the university. Push for the company to own all improvements its people develop, with the university’s rights confined to the defined background IP.
The Licence: Where the Value Lives
Universities rarely assign patents outright to a spinout at formation; the standard structure is an exclusive licence, with an assignment sometimes negotiable later or on milestones. But “exclusive” is a term of art with a sting. Under the Patents Act 1990 (Cth), an exclusive licensee can sue infringers under section 120 (joining the patentee) — but only a true exclusive licensee: one granted the whole, indivisible right to exploit the patent in Australia, to the exclusion of the patentee and everyone else. In Bristol-Myers Squibb v Apotex [2015] FCAFC 2, the Full Federal Court held that a licence in which the patentee reserved any exploitation right — there, manufacturing — did not confer that status, and the licensee had no standing to sue. A field-of-use-limited licence, or one where the university reserves rights to exploit, will generally fail the same test. If standing to sue matters (and your investors will assume it does), structure the university’s retained academic use as a licence-back under a licence of the entire right, rather than a reservation — or accept that enforcement runs through the university and deal with that expressly. The terms that decide whether the licence is fundable:
- Field of use and territory. TTOs often licence narrowly — one application, one field. That protects the university’s ability to licence elsewhere, but a spinout that pivots outside its field owns nothing. Negotiate the broadest field you can credibly develop, worldwide, with sublicensing rights.
- Diligence milestones. Expect development and commercialisation milestones with termination or conversion to non-exclusivity if missed. Make them realistic, make cure rights explicit, and resist automatic termination — an investor will not fund a company whose core asset can evaporate on a missed date.
- Termination triggers. Termination on insolvency events or change of control is common in first drafts and toxic to an exit. An acquirer is buying the licence; if the licence dies at completion, so does the deal.
- Reserved rights and publication. Universities will retain rights to use the IP for research and teaching — structured as a licence-back if section 120 standing matters, per above — and academics will want to publish. That’s fine — but build in a review window (30–60 days is typical) so patent filings can go in before disclosure destroys novelty. This interacts directly with your patent filing strategy.
- Payments. Upfront fees are usually modest or deferred for spinouts; the university’s return comes through equity, milestone payments and royalties. Watch royalty stacking — if you’ll need third-party licences too, negotiate a stacking clause that reduces the university’s royalty when combined royalties pass a threshold.
Since 2022, the Commonwealth’s Higher Education Research Commercialisation IP Framework has offered voluntary standard agreements — including licence and assignment templates — designed to cut negotiation time and anchor terms at something like market. Universities aren’t obliged to use them, but they’re a useful benchmark when a TTO’s first draft is a long way from founder-friendly.
Equity: What the University Takes
Australian universities take founding equity in their spinouts, and practice varies enormously — surveys of Australasian institutions put stakes anywhere from single digits to 50% at formation, depending on the institution, the technology’s maturity and what the licence costs in cash. Three points of negotiation matter more than the headline number:
- Dilution. The university should hold ordinary shares that dilute like everyone else’s. Anti-dilution protection or a right to maintain percentage ownership is a red flag every VC will price against you — the same power-dynamics reading you’d apply to any term sheet.
- Control. Universities sometimes ask for a board seat or veto rights. An observer seat and information rights are usually the better landing point; keep the cap table and register clean from day one.
- Founder equity is separate. The academic founders’ personal stakes, vesting and ongoing university employment (most stay on part-time) raise conflict-of-interest processes inside the university — start those early, as they can add months.
Also check the structural boxes investors care about: a young company (broadly, one incorporated within the last three income years — or up to six, where total expenses across the last three income years were $1 million or less — that meets the ATO’s early stage and innovation tests) will often want to preserve ESIC eligibility for its angels. And map the grant landscape early: Australia’s Economic Accelerator funded over 400 commercialisation projects from 2023, but the 2026–27 Budget ended funding for new AEA projects beyond 2025–26, so check what’s actually open — state programs, CSIRO ON and university-linked funds among them — before you build grant money into the runway plan.
The Bottom Line
A university spinout is only as strong as its chain of title and its licence. Verify the university actually owns what it’s licensing — staff contracts and student assignments included — then negotiate the licence like the core asset it is: broad field, realistic milestones, no fragile termination triggers, improvements owned by the company. Take the university’s equity as ordinary, diluting shares, and use the HERC framework as your benchmark for market terms. Do it properly at formation, and the licence becomes a due diligence asset instead of the reason your round stalls.
This article is general information only, not legal advice — spinout deals turn on the specific university’s policies, the state of the IP and the funding path ahead. Viridian Lawyers advises Australian founders, research institutions and investors on technology transfer, licensing and venture financing. If you’re negotiating with a TTO — or investing in a company that did — get in touch before the licence is signed.
